GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-4.97%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$532M
AUM Growth
+$532M
(+6.5%)
Cap. Flow
+$72.8M
Cap. Flow
% of AUM
13.7%
Top 10 Holdings %
Top 10 Hldgs %
50.02%
Holding
51
New
12
Increased
11
Reduced
10
Closed
9
Top Buys
| 1 |
UroGen Pharma
URGN
|
$36.7M |
| 2 |
Alkermes
ALKS
|
$13M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$11.7M |
| 4 |
PTC Therapeutics
PTCT
|
$11.2M |
| 5 |
Replimune Group
REPL
|
$10.9M |
Top Sells
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$20.9M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$12.7M |
| 3 |
Viking Therapeutics
VKTX
|
$9.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
$9.31M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$6.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
-968,795
| Closed | -$20.9M |
|